Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

(2017) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond

(2016) Ziqiang Zhu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

(2016) Selma Ugurel et al.   EUROPEAN JOURNAL OF CANCER

Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor

(2016) An Liu et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

(2016) Ashley Cimino-Mathews et al.   HUMAN PATHOLOGY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

(2015) B Homet Moreno et al.   BRITISH JOURNAL OF CANCER

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

The risk of second primary cancers in clear cell and papillary renal cancer.

(2015) Muhammad Saad Hamid et al.   JOURNAL OF CLINICAL ONCOLOGY

Human PD-1 binds differently to its human ligands: A comprehensive modeling study

(2015) Clement Viricel et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Nivolumab success in untreated metastatic melanoma

(2015) Emma Wilkinson   LANCET ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections

(2015) Ahmed F. Abdel-Magid   ACS Medicinal Chemistry Letters

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

(2014) Laurie H. Sehn et al.   BLOOD

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Pembrolizumab: First Global Approval

(2014) Raewyn M. Poole   DRUGS

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies

(2014) Kent Shih et al.   DRUGS

Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma

(2014) Ya-Wen Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

3-Substituted-N-(4-Hydroxynaphthalen-1-yl)arylsulfonamides as a Novel Class of Selective Mcl-1 Inhibitors: Structure-Based Design, Synthesis, SAR, and Biological Evaluation

(2014) Fardokht A. Abulwerdi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Pembrolizumab for treatment of refractory melanoma

(2014) Sanjeet Bagcchi   LANCET ONCOLOGY

Antibodies to watch in 2015

(2014) Janice M Reichert   mAbs

The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells

(2014) YOU CHENG ZHANG et al.   Molecular Medicine Reports

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells

(2014) Hatem Soliman et al.   PLoS One

Lymphocyte Activation Gene-3 (LAG-3) Negatively Regulates Environmentally-Induced Autoimmunity

(2014) Vibha Jha et al.   PLoS One

Immune checkpoints in cancer clinical trials

(2014) Elad Sharon et al.   Chinese Journal of Cancer

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

(2014) David A Schaer et al.   Journal for ImmunoTherapy of Cancer

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

(2013) Omid Hamid et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

(2013) Li Shi et al.   Journal of Hematology & Oncology

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

(2012) Timothy S. Fisher et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review

(2011) Naval Bajwa et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Therapeutic targeting of B7-H1 in breast cancer

(2011) Amal Hasan et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

How I treat elderly patients with diffuse large B-cell lymphoma

(2010) M. Pfreundschuh   BLOOD

Disrupting protein–protein interactions with non-peptidic, small molecule α-helix mimetics

(2010) Christopher G Cummings et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Germinal-Center T-Helper-Cell Markers PD-1 and CXCL13 Are Both Expressed by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma

(2008) Hongbo Yu et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA